Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : ASTM-AASTROM BIOSCIENCES: STEM CELL RESEARCH -- Ignore unavailable to you. Want to Upgrade?

To: JEB who wrote (482)	12/31/1998 9:03:00 AM
From: John G. Mueller	Respond to of 1084

From Yahoo News: For complete story see:http://biz.yahoo.com/prnews/981231/ca_burrill_1.html For 1999, Burrill & Company sees: * a general improvement in the equity markets for biotechs: * with the Asian economic crisis lessening and a general improvement in the world's equity markets, the markets for biotechs will similarly improve; * increased interest by the investment community in Europe in equities (in general) and biotechnology specifically will add dramatically to biotech company's abilities to assess its capital needs; * large capitalization biotech stocks have led the recovery to date, smaller capitalization stocks (which have been hurt more) should now recover as more investors return to small capitalization stocks where values are disproportionately low * product approvals and product market success will drive earnings and company success and the markets will react favorably; * venture capital interest will return as values become more apparent and liquidity re-emerges; * selected acquisitions of biotechs will provide evidence of the company's inherent values. * improved regulatory success from changes made during the last several years increasing both the predictability and rapidity of approval. * an increased number of product approvals is expected for 1999; * products expected to be approved include Coulter's Bexxar for non-Hodgkin's lymphoma, Centocor's Remicade for rheumatoid arthritis, Biota/Glaxo Wellcome's new agent for influenza, Relenza, and Genentech/Alkermes' depot formulation of human growth hormone, Nutropin Depot. * Industry consolidation will continue, with increases in the biotech to biotech merger arena, but reduced big pharma/biotech consolidation because partnering will play a more important role. * Partnering between big and small companies increasing in both number and size as large pharma/agricultural companies will increasingly access innovation from the smaller companies. * Internationalization of biotech will continue, with more cross border deals, more cross border financing and more broad based developments worldwide. * Genomics will continue to drive industry restructuring as the breadth of genomic knowledge, understanding of disease pathways, bioinformatics, and more sophisticated tools revolutionizes agriculture and human health. * Agbio, animal health and nutraceuticals will increase in importance as the industry again transforms itself (no longer a biotech industry just focused on human healthcare therapeutics and diagnostics). * Genetics in the food chain and bioethics will become a bigger issue in 1999 as consumer awareness increases and human cloning experiments continue to "push the envelope." Improving the inputs/outputs of agriculture should have less emotion than the "human engineering" dialogue, but both will become bigger issues. Happy New Year! John